Comparative Pharmacology
Head-to-head clinical analysis: ATRACURIUM BESYLATE versus MIVACURIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATRACURIUM BESYLATE versus MIVACURIUM CHLORIDE.
ATRACURIUM BESYLATE vs MIVACURIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine binding and causing skeletal muscle relaxation.
Mivacurium chloride is a non-depolarizing neuromuscular blocking agent that competitively binds to nicotinic acetylcholine receptors at the motor end-plate, preventing acetylcholine from binding and thereby inhibiting neuromuscular transmission. It is a mixture of stereoisomers and is rapidly hydrolyzed by plasma cholinesterase.
0.4–0.5 mg/kg IV bolus for intubation; maintenance: 0.08–0.1 mg/kg IV as needed or infusion 5–10 mcg/kg/min
0.15-0.25 mg/kg IV bolus for endotracheal intubation; maintenance infusion: 0.5-1.5 mcg/kg/min IV
None Documented
None Documented
Clinical Note
moderateAtracurium besylate + Tranilast
"Atracurium besylate may increase the neuromuscular blocking activities of Tranilast."
Clinical Note
moderateAtracurium besylate + Tolfenamic acid
"Atracurium besylate may increase the neuromuscular blocking activities of Tolfenamic acid."
Clinical Note
moderateAtracurium besylate + Nimesulide
"Atracurium besylate may increase the neuromuscular blocking activities of Nimesulide."
Clinical Note
moderateAtracurium besylate + Risedronic acid
Terminal elimination half-life is approximately 20 minutes (range 15-25 min) in healthy adults. Clinical context: Recovery from neuromuscular blockade is faster than for nondepolarizing relaxants cleared renally. Half-life may be prolonged in hypothermia or acidosis but is minimally affected by renal or hepatic impairment.
Terminal elimination half-life is approximately 2 minutes (range 1-3 minutes) for the initial rapid distribution phase, and the elimination half-life is about 17-20 minutes in patients with normal renal function. Clinically, this short half-life allows for rapid recovery of neuromuscular function.
Renal (50-60% unchanged), biliary/fecal (20-30% as metabolites, mainly laudanosine), and Hofmann elimination (non-enzymatic, pH- and temperature-dependent) accounts for approximately 40-50% of clearance.
Primarily renal excretion of unchanged drug and metabolites; approximately 90-95% eliminated via urine, with less than 5% in feces. Minor biliary excretion.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker
"Atracurium besylate may increase the neuromuscular blocking activities of Risedronic acid."